SCHEMBL347940

SCHEMBL347940

CCOC(=O)c1sc(Nc2ccccc2N)nc1C

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.71
ALDH1A1 P00352 6/20 0.71
MEN1 O00255 5/20 0.71
KMT2A Q03164 5/20 0.71
NPSR1 Q6W5P4 4/20 0.71
NPC1 O15118 6/20 0.70
RAB9A P51151 5/20 0.70
CASP3 P42574 1/20 0.70
SENP8 Q96LD8 1/20 0.70
SENP7 Q9BQF6 1/20 0.70
SENP6 Q9GZR1 1/20 0.70
HPGD P15428 3/20 0.70
KDM4E B2RXH2 8/20 0.64
LMNA P02545 3/20 0.64
DHODH Q02127 5/20 0.63
SMN1; SMN2 Q16637 4/20 0.61
CYP2C9 P11712 1/20 0.58
APOBEC3G Q9HC16 1/20 0.56
USP2 O75604 1/20 0.55
GAA P10253 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27957021 0.83 MAPT (0.54) MAPTALDH1A1MEN1KMT2ANPSR1
SCHEMBL2885791 0.82 MAPT (1.00) MAPTALDH1A1MEN1KMT2ANPSR1
SCHEMBL12158147 0.76 MAPT (0.71) MAPTALDH1A1MEN1KMT2ANPSR1
SCHEMBL3046343 0.76 ALDH1A1 (0.70) MAPTALDH1A1MEN1KMT2ANPSR1
SCHEMBL12296366 0.76 MAPT (0.79) MAPTALDH1A1MEN1KMT2ANPSR1
SCHEMBL3584407 0.75 SMN1; SMN2 (0.80) MAPTALDH1A1MEN1KMT2ANPSR1
SCHEMBL12158131 0.75 MAPT (0.84) MAPTALDH1A1MEN1KMT2ANPSR1
SCHEMBL18320945 0.75 KDM4E (1.00) MAPTALDH1A1MEN1KMT2ANPSR1
SCHEMBL1541108 0.75 MAPT (0.65) MAPTALDH1A1MEN1KMT2ANPSR1
SCHEMBL10288174 0.74 CDC7 (0.67) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318949-B2 Organic compounds NOVARTIS AG (CH) 2012-11-27 US disclosed
US-20120014906-A1 ORGANIC COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2012-01-19 US disclosed
US-8049016-B2 Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes NOVARTIS AG (CH) 2011-11-01 US disclosed
CN-102007123-A Heterocyclic inhibitors of stearoyl-CoA desaturase NOVARTIS AG 2011-04-06 CN disclosed
US-20090264444-A1 Organic compounds XENON PHARMACEUTICALS INC. (CA) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120014906-A1 ORGANIC COMPOUNDS SCD, SCD5, FADS2 MAPT 2947/4885ALDH1A1 451/4885MEN1 4876/4885
US-20090264444-A1 Organic compounds SCD, SCD5, FADS2 MAPT 2947/4885ALDH1A1 451/4885MEN1 4876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.